INTRODUCTION
Childhood cancer survivorship has attracted attention globally, in part, because of the decades of life saved for every child with cancer and an everincreasing number of survivors, which necessitates an understanding of the quality of survival. 1 Cancer therapy at an early age can produce complications that may not become apparent until years later, hence the term late effect for a long-term outcome that persists or that develops several years after cancer is diagnosed. A comprehensive evaluation of these late effects requires carefully constructed cohorts that are sufficiently large and observed for extended periods. Prohibitive costs associated with detailed clinical evaluation of these large cohorts often necessitate reliance on self-reporting or linkage with registries, both of which have attendant limitations. Detailed clinical evaluations have been attempted by using the cooperative group infrastructure, with the accompanying advantage of a multi-institutional setting and an established clinical infrastructure but with the distinct disadvantage of attrition after 5 to 7 years from diagnosis. Detailed clinical evaluations have also been performed in single-institution settings where extensive infrastructure has been developed to observe cohorts for extended time. The single-institution cohorts are generally smaller than the large multi-institutional or population-based cohorts that use self-reporting or registry linkage to ascertain outcomes. Furthermore, single-institution cohorts may suffer from homogeneity of therapeutic exposure, and they are resource intensive. Nonetheless, complementary and often additive information can be gleaned from the various settings, allowing for a comprehensive picture of the landscape in cancer survivorship to emerge. Select findings from such initiatives are described here.
Survivor Research Program; the Australian cohort of childhood cancer survivors, New South Wales population; and the French and British cohort of childhood cancer survivors. Salient features of select cohorts are summarized in Table 1 . Characteristics unique to the cohorts are summarized in the Appendix (online only).
COOPERATIVE GROUP STUDIES
Cooperative groups offer unique opportunities to investigate adverse events encountered during treatment and in the first few years after treatment is completed. Cooperative group trials also provide opportunities to investigate treatment-related complications in the context of therapeutic randomization. Children's Oncology Group (COG), a National Cancer Institute-supported clinical trials network, includes more than 200 children's hospitals, universities, and cancer centers committed to conducting translational research to improve outcomes in children with cancer. 2 Examples of risk-reduction strategies in COG include random assignment of patients to receive dexamethasone versus prednisone to treat acute lymphoblastic leukemia (ALL), anthracyclines with cardioprotection versus anthracyclines without cardioprotection, and chest irradiation versus no chest irradiation for Hodgkin lymphoma (HL) in girls. 3 These trials offer opportunities to understand the role of specific therapeutic exposures in the development of adverse outcomes. Investigators in the COG ALTE11C2 study are using such an opportunity by examining cardiac outcomes in long-term survivors of HL and ALL treated in COG legacy trials Pediatric Oncology Group (POG) 9425, 9426, and 9404 in which patients were randomly selected to receive anthracycline with or without dexrazoxane cardioprotection in the setting of comparable eventfree and overall survival in the two arms. 4, 5 Female adolescents exposed to high-dose alkylating agents and/or ovarian irradiation are at risk for accelerated depletion of ovarian reserve, resulting in premature menopause or acute ovarian failure. 6 COG ALTE11C1 researchers are using a prospective longitudinal study design to characterize change in ovarian reserve during and shortly after completion of gonadotoxic therapies. The data will inform the natural history of ovarian function before the onset of clinically apparent premature menopause or acute ovarian failure. These findings can inform counseling and opportunities for the cryopreservation of oocyte and ovarian tissue in individuals at highest risk for ovarian failure. 6 Utilizing the well-established clinical trials infrastructure in COG, researchers are currently developing interventional trials COG ALTE1331 and COG ALTE1431 to test strategies to implement before the onset of clinically apparent cardiovascular disease.
BURDEN OF MORBIDITY
Investigators from several studies have described the burden of morbidity that survivors of childhood cancer carry by using methods that range from self-reporting to comprehensive clinical assessment. The magnitude of this burden has varied across the studies and has depended on the method of ascertainment of long-term health conditions and the length of follow-up. Common Terminology Criteria for Adverse Events from the National Cancer Institute were applied to the CCSS cohort to characterize the overall chronic disease burden borne by survivors. Overall, 62.3% of survivors had at least one chronic condition, placing the cohort at a 3.3-fold increased risk of any longterm health condition compared with age-and sex-matched siblings. Of more importance, 27.5% of the CCSS cohort had a severe and/or life-threatening condition, placing them at an 8.2-fold increased risk compared with that of the sibling comparison group. 7 The risk of severe and/or life-threatening conditions in the CCSS cohort was highest among survivors of bone tumor (38.9-fold increased risk) and lowest among survivors of leukemia or Wilms tumor (4.1-fold increased risk) compared with siblings. Risk of severe and/or lifethreatening conditions increased 12.6-fold for survivors of CNS tumors, 10.2-fold for survivors of HL, 8.9-fold for survivors of sarcoma, 6.8-fold for survivors of NHL, and 4.7-fold for survivors of neuroblastoma. The SCCSS revealed severe outcomes in one third of survivors. 8, 9 By the age of 50 years, the cumulative incidence of severe, disabling, life-threatening, and/or fatal health conditions in the CCSS cohort was 53.6%. 10 Furthermore, among survivors who reached age 35 years without a previous severe and/or life-threatening condition, 25.9% experienced a subsequent condition within 10 years.
The overall burden of chronic disease has also been evaluated at single institutions, with detailed medical assessment of survivors. In a cohort of 1,362 survivors of childhood cancer treated at the Emma Children's Hospital/Academic Medical Center, 11 75% had one or more adverse events, and 40% had one or more severe, lifethreatening, and/or disabling adverse events. On the basis of data from medical assessments of the SJLIFE cohort, the estimated cumulative prevalence for a serious and/or disabling or life-threatening chronic condition was 80.5% (95% CI, 73.0% to 86.6%) by the of age 45 years (Fig 1) .
SUBSEQUENT MALIGNANT NEOPLASM
Subsequent malignant neoplasms (SMNs) are histologically distinct malignancies that develop among patients treated for a primary malignancy. Although a few SMNs are attributable to heritable conditions such as retinoblastoma or neurofibromatosis, the vast majority of SMNs observed in survivors of childhood cancer are largely attributed to the genotoxic insult resulting from therapeutic exposures. The unique role played by specific therapeutic exposures in the development of SMNs has resulted in their classification into two distinct categories. The first is chemotherapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML), and the second is radiationrelated solid SMNs. Characteristics of t-MDS/AML include a short latency of Ͻ 3 years after the diagnosis of primary cancer diagnosis and an association with alkylating agents and/or topoisomerase II inhibitors. 12 Solid SMNs are strongly associated with irradiation and are characterized by a latency that exceeds 10 years. 12 Nonmelanoma skin cancers (NMSC), breast cancer, CNS tumors, thyroid cancer, genitourinary cancers, digestive tract tumors, bone tumors and SMNs of respiratory sites are the most common solid SMNs observed among survivors of childhood cancer. study-specific variability in the observed excess risk of SMNs compared with that of the general population is attributable to the difference in the length of follow-up and the age of the survivors cohort. The 30-year cumulative incidence in the CCSS cohort was 9.1% for NMSC, 7.9% for SMN excluding NMSC, and 3.1% for meningioma. 15 Population-based registry data from the ALiCCS yielded an absolute excess risk (AER) of three to six per 1,000 person-years of follow-up. 13 The BCCSS cohort demonstrated that 52% of the excess cancers observed among those age 40 years or older was attributable to digestive, genitourinary, breast, or respiratory sites.
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14 Finally, the CCSS cohort showed that patients with SMNs remain at considerable risk for additional subsequent neoplasms. 17 Survivors of medulloblastoma had the highest 30-year cumulative incidence of meningioma (16.4%).
15
Exquisitely detailed therapeutic exposures enabled detailed assessment of the dose-response relationship between radiation exposure and the risk for breast cancer (Fig 2A) , 18 CNS SMNs (Fig 2B) , 19 thyroid tumors, 20 and NMSC 21 in the CCSS cohort. Furthermore, both the CCSS 22 and the BCCSS 14 have shown that the risk of sitespecific SMNs is comparable with that observed among individuals at increased risk for cancer because of genetic susceptibility. Therefore, among female survivors of HL exposed to chest irradiation in the CCSS cohort, the cumulative incidence of breast cancer was 35% by age 50 years, a rate comparable with that of carriers of a BRCA mutation in the general population. 22 The cumulative incidence of colorectal cancer by age 50 years after exposure to abdominopelvic irradiation was 1.4% in the BCCSS cohort. This was comparable with the 1.2% risk observed in individuals with two or more age-and sex-matched first-degree relatives with colorectal cancer.
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HL
Survivors of HL in the CCSS cohort had the highest 30-year cumulative incidence of SMNs excluding NMSCs (18.4%). 15 The incidence of invasive solid SMN surpasses the risk of relapse by 20 years after diagnosis. The median time to the first solid SMN was 18.7 years after diagnosis. 23 The cumulative incidence was higher for female survivors (26.1%) than for male survivors (10.9% at 30 years). The higher incidence among female survivors primarily derived from their high incidence of breast cancer. Compared with the general US population, the standardized incidence ratios (SIRs) were highest for the solid epithelial cancers, bone cancer (22.3), thyroid cancer (17.6), and breast cancer (17.0). The cumulative incidence of invasive breast cancer was 18.3% at 30 years. The cumulative incidence of NMSC was 16.7% at 30 years. The BCCSS showed the survivors of childhood HL had a 5.6-fold increased risk of subsequent neoplasms compared with the general population.
14 The risk was 8.9ϫ that of the general population for breast cancer, and 27.7ϫ that of the general population for bone tumors.
ALL
The CCSS demonstrated that survivors of childhood ALL had a 4.4-fold increased risk of invasive SMNs. The excess absolute risk was 1.4 per 1,000 person-years of observation, and the 30-year cumulative incidence was 5.2%. 15 The most common subsequent neoplasm was NMSC (40%), followed by meningioma (20%), glial tumors (8%), breast cancer (3%), soft tissue sarcomas (3%), and other tumors (26%).
A cohort of 8,831 children with ALL given legacy COG therapeutic protocols between 1983 and 1995 had a risk of SMN that was 7.9ϫ higher than that observed in the general population. 24 The risk was 
CARDIOVASCULAR OUTCOMES
The CCSS cohort has demonstrated that aging adult survivors are at increasing risk for treatment-associated cardiotoxicity 25 and stroke.
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Among recipients of cardiotoxic agents in the SJLIFE cohort, the cumulative prevalence of select cardiac outcomes by age 50 years was 24% for cardiomyopathy, 25% for coronary artery disease, 86% for valve disorders, and 42% for conduction disorders. 27 In a cohort of 1,362 survivors of childhood cancer treated at Emma Children's Hospital/Academic Medical Center, the 30-year cumulative incidence of symptomatic cardiac events was 12.6% after exposure to anthracyclines and chest irradiation; it was 7.3% after anthracycline exposure alone and 4.0% after chest irradiation alone. 28 An exponential relationship was demonstrated between the risk of cardiac event and cardiotoxic therapeutic exposure (cumulative dose of anthracyclines and/or radiation dose). 28 Again, the observed variability in the prevalence of cardiac disorders among various studies likely depends on the method by which outcomes were ascertained, that is, self-reporting versus clinical screening.
Survivors of childhood cancer are at risk for a constellation of cardiovascular risk factors, such as hypertension, diabetes, and dyslipidemia.
29,30 Survivors of ALL from the SJLIFE cohort had a higher risk of the metabolic syndrome (relative risk [RR], 1.4), hypertension (RR, 2.4), low HDL (RR, 1.4), obesity (RR, 1.5) and insulin resistance (RR, 1.6) than that of age-, sex-, and race-matched control subjects from the National Health and Nutrition Examination.
31 Metabolic syndrome was associated with older age and previous cranial radiotherapy. In another single-institution study, the prevalence of metabolic syndrome was 13%, and survivors of ALL treated with cranial irradiation were at increased risk for metabolic syndrome.
32 Survivors in the CCSS who received total-body irradiation (odds ratio [OR], 7.2), abdominal irradiation (OR, 2.7), or alkylating agents (OR, 1.7) at a young age were at increased risk for diabetes mellitus.
33
Data from the CCSS demonstrated that cardiovascular outcomes experienced by survivors of childhood cancer are potentiated by modifiable cardiovascular risk factors that are components of metabolic syndrome. 34 Observations from nononcology populations support the benefits of interventions to reduce these modifiable risk factors, which include obesity, smoking, hypertension, diabetes, and dyslipidemia. 35, 36 In line with this observation, adherence to a heart-healthy lifestyle was associated with lower risk of metabolic syndrome in the oncology population. 37 Findings from studies in nononcology populations suggest that routine screening for these risk factors may be beneficial, setting the stage for possible interventions to mitigate adverse cardiovascular outcomes in survivors of cancer.
NEUROMUSCULAR OUTCOMES
Data from the SJLIFE cohort support an association between exposure to vinca alkaloids and motor impairment, and between cisplatin exposure and sensory impairment. Patients exposed to vinca alkaloids had a 1.7-fold increased risk of motor neuropathy, and those exposed to cisplatin had a 1.6-fold increased risk of sensory neuropathy compared with unexposed individuals. 38 Findings from the SJLIFE cohort also demonstrated that the prevalence of frailty among survivors of childhood cancer in their 30s was comparable to that of adults older than 65 years. 39 An important finding was that frail survivors have a 2.6-fold higher risk of death and a 2.2-fold higher risk of developing a new chronic condition than that of nonfrail survivors.
ENDOCRINE AND REPRODUCTIVE OUTCOMES
ALiCCS reports confirm that endocrine disorders are a major health problem in survivors of childhood cancer, with an AER of four excess endocrine disorders per 1,000 person-years of follow-up. 40 ,41 A variety of endocrine and reproductive outcomes have been described in the SJLIFE cohort.
27,42-44 Survivors exposed to radiation developed 45 The SJLIFE study demonstrated that serum inhibin B and follicle-stimulating hormone lack specificity as a surrogate for sperm concentration.
43 A dose-related decline in sperm concentration is associated with increasing cyclophosphamide equivalent dose and an absence of a threshold dose predictive of impaired spermatogenesis or azoospermia.
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LATE MORTALITY
The CCSS cohort had an 8.4-fold increased risk of premature death compared with the general population.
46 Figure 3 displays the allcause mortality of 5-year survivors of childhood cancer compared with age-adjusted expected survival rates in the US population. The BCCSS cohort had a 10.7-fold increased risk of death, 47 and the ALiCCS cohort had an 8.3-fold increased risk of death.
48 A singlecenter cohort from DCOG LATER demonstrated a 17-fold increased risk of late mortality. 49 Both the CCSS and BCCSS cohorts demonstrated changing patterns of cancer-specific mortality with increasing time from diagnosis (Fig 3B) . 47, 50 In the BCCSS cohort, the AER for deaths from recurrence declined with time, whereas the AER for deaths from SMNs and cardiovascular causes increased. Subsequent to 45 years after diagnosis, recurrence accounted for only 7% of the excess number of deaths, whereas SMNs and cardiovascular causes accounted for 51% and 26% of the excess number of deaths, respectively. 47 The CCSS cohort had a 15.2-fold increased risk of SMNrelated deaths, an 8.8-fold increased risk of pulmonary deaths, and a seven-fold increased risk of death from cardiac causes compared with the general population.
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GENETIC SUSCEPTIBILITY TO TREATMENT-RELATED ADVERSE OUTCOMES
The observed interindividual variability in the risk for treatmentrelated complication suggests a role for individual genetic susceptibility. 51 A large multi-institutional case-control study within COG, COG ALTE03N1, is being conducted to address this question in patients with SMNs, stroke, cardiomyopathy, or osteonecrosis. DNA and RNA are procured from case patients with the aforementioned adverse events and matched control subjects who are survivors of cancer with no adverse events to examine the role of genetic susceptibility and gene-environment interactions in the development of treatmentrelated adverse events. CCSS researchers, in collaboration with the Division of Cancer Epidemiology and Genetics at the National Cancer Institute, have studied the genotypes of almost 6,000 survivors of childhood cancer using the Illumina HumanOmni5Exome microarray to investigate genetic contributions to the development of subsequent neoplasms and specific SMNs. This resource will be made available to investigators interested in genetic susceptibility to nonmalignant late effects.
Regarding genetic susceptibility to anthracycline-related cardiomyopathy, carbonyl reductases catalyze the reduction of anthracyclines to cardiotoxic alcohol metabolites; polymorphisms in CBR3 influence synthesis of these metabolites. Recent findings from study COG ALTE03N1 suggest that homozygosis for the G allele of CBR3 contributes to an increased risk of cardiomyopathy associated with low-to-moderate dose anthracyclines (Fig 4A) .
52 COG ALTE03N1
Survival Function Estimate
All-Cause Mortality (cumulative prevalence) investigators also identified the common single nucleotide polymorphism rs2232228 in the hyaluronan synthase gene HAS3 that exerts a modifying effect on anthracycline dose-dependent risk of cardiomyopathy (Fig 4B) . 53 In individuals exposed to high-dose anthracyclines Ͼ 250 mg/m 2 , the rs2232228 AA genotype conferred an 8.9-fold increased risk of cardiomyopathy compared with the GG genotype. The high cardiomyopathy risk associated with the AA genotype could be a result of inadequate remodeling and/or inadequate protection of the heart from reactive oxygen species-mediated injury induced by high anthracycline exposure. Finally, in a study representing a collaboration between Canada and the Netherlands, investigators identified multiple genetic variants in SLC28A3 and other genes associated with anthracycline-related cardiotoxicity. 54 Combined with clinical risk factors, genetic risk profiles were predictive of cardiotoxicity in 75% of the individuals at high risk.
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LONG-TERM FOLLOW-UP GUIDELINES
The Institute of Medicine strongly recommends that all survivors of childhood cancer receive regular medical care that is adapted to the specific risks that arise from their previous cancer therapy, genetic predispositions, lifestyle, and any comorbid health conditions. 55 CCSS data suggest that patients examined by a primary care clinician are less likely than those evaluated at a cancer center to receive indicated echocardiography (22% v 53%) or mammography (35% v 62%). 56 Similar findings from SCCSS demonstrate that only a minority of adult survivors of childhood cancer undergo regular follow-up, and few receive written documentation on their diagnosis, therapy, and advice for future medical check-ups. 57 These findings suggest that survivors of childhood cancer and their healthcare providers could benefit from standardized, risk-based recommendations for early detection of long-term complications. Both oncology and nononcology providers have endorsed the need for such guidelines because of their lack of familiarity with the unique health risks associated with treatment for childhood cancer.
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Several groups, such as the US COG, Scottish Intercollegiate Guidelines Network, DCOG LATER, and the United Kingdom Children's Cancer Study Group Late Effects Group, have developed recommendations for follow-up of survivors of childhood cancer.
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Evidence from literature is used to identify high-risk groups, whereas screening recommendations are derived by means of expert consensus to match the magnitude of risk with the intensity of screening recommendations. 65 In addition, guidelines also provide resources for patient counseling and education. Standardizing the follow-up care of survivors of childhood cancer provides opportunities to refine guidelines by examining the yield from observing them and by determining their cost effectiveness, as described next.
YIELD OF RISK-BASED SCREENING FOR LONG-TERM COMPLICATIONS
Using the COG Long-Term Follow-Up Guidelines, 64 investigators at a single institution conducted 4,992 tests in survivors of childhood cancer during 1,188 clinic visits to determine the yield of exposuredriven, risk-based screening for the early detection of long-term complications. 66 High-yield tests included thyroid function assessment, which revealed hypothyroidism in 10.1% of survivors; audiometry, which showed hearing loss in 22.6%; dual-energy x-ray absorptiometry, which yielded low bone mineral density in 23.2%; serum ferritin testing, which demonstrated iron overload in 24.0%; and pulmonary function testing, which indicated pulmonary dysfunction in 84.1%. Screening tests with a negligible or negative yield of Ͻ 1% included complete blood counts to detect therapy-related leukemia; dipstick urinalysis to detect proteinuria; serum blood urea nitrogen and/or creatinine assessment to detect glomerular defects, microscopic urinalysis to detect hematuria indicative of hemorrhagic cystitis or bladder cancer; and ECG for anthracycline-related conduction disorder. A similar evaluation among SJLIFE cohort members demonstrated that the highest prevalence of adverse outcomes affected pulmonary, neurosensory, endocrine, reproductive, cardiovascular, and neurocognitive function. 27 These findings led to refinement of COG Long-Term Follow-Up Guidelines with the elimination of screening tests with low yield.
COST-EFFECTIVENESS OF LONG-TERM FOLLOW-UP GUIDELINES
The COG Long-Term Follow-Up Guidelines recommend lifetime echocardiographic screening for asymptomatic left ventricular dysfunction. The effectiveness and cost-effectiveness of the COG guidelines was evaluated by simulating life histories by using Markov health states.
67 COG guidelines reduced the risk of heart failure in survivors of childhood cancer at a cost of less than $100,000 per quality-adjusted life year. Furthermore, the study revealed less-frequent screening schedules that achieved most of the benefits and that were more cost-effective than those stated in the COG guidelines.
INTERNATIONAL LATE EFFECTS OF CHILDHOOD CANCER GUIDELINE HARMONIZATION GROUP
In 2010, the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) was organized to establish an integrated strategy for the surveillance of late effects in survivors of childhood cancer worldwide. 68 The IGHG uses a consistent, evidencebased method that adheres to the Appraisal of Guidelines for Research and Evaluation Collaboration 69 and the standards for Developing Trustworthy Clinical Practice Guidelines of the Institute of Medicine. 70 In the IGHG, concordance and discordance and evidence that support recommendations in existing national guidelines are evaluated for each topic. The literature is systematically searched for relevant questions, and extensive evidence summaries for the risk groups, accuracy of screening tests, and potential treatment options are organized. 68 Screening and/or surveillance recommendations are developed and graded by using elements of established recommendations. 71, 72 Harmonization has been completed and its results published for the surveillance of breast cancer 73 and cardiomyopathy. 74 Harmonization efforts are ongoing for the surveillance of gonadal toxicity, thyroid cancer, and CNS neoplasm.
CONCLUSIONS AND FUTURE DIRECTIONS
Improved understanding of treatment-related toxicity has guided not only the adoption of less-toxic therapies but also the development of treatment summaries, survivorship plans, and efforts to harmonize survivorship guidelines worldwide. 68 Research into cancer survivorship will continue to evolve as better treatment options, new agents, and combinations of agents are developed. Although targeted therapies will likely prolong survival, many of the agents used in the past 40 years will continue to be included in the treatment of most pediatric patients with cancer. 75 Refinements in radiation therapy and minimally invasive surgeries are intended to minimize late effects. More recent cohorts of children with cancer must still be observed to determine how modifications to therapy affect the prevalence and spectrum of late effects. The growing population of survivors provides numerous opportunities for research related to the etiology of cancer and other late effects. Detailed knowledge of therapeutic exposures coupled with close follow-up after exposure enable researchers to study testable hypotheses and to determine the effects of host and therapy-related factors in the development of adverse outcomes ranging from carcinogenesis to organ dysfunction.
Opportunities also exist to explore gene-environment interactions that may modify susceptibility to adverse outcomes and thus provide insights into the identification of high-risk populations. It is also important to develop and test interventions that can reduce the effect of cancer and its treatment on morbidity and mortality in survivors of childhood cancer. For example, survivors of HL treated with chest irradiation are at risk for developing lung cancer, and tobacco use increases this risk 20-fold. Successful smoking prevention and/or cessation strategies among survivors can decrease their risk while also decreasing the development and progression of atherosclerosis and other SMNs. Female survivors of cancer treated with chest irradiation are at increased risk for breast cancer, providing an opportunity to develop therapeutic strategies to reduce this risk. These strategies can be surgical intervention, such as prophylactic mastectomy or bilateral oophorectomy, or hormonal chemoprevention.
Survivors of childhood cancer, particularly those who received irradiation of the hypothalamic-pituitary axis, are also at risk for obesity. Obesity, in turn, can exacerbate the alreadyincreased risks of cardiovascular disease associated with anthracycline therapy and radiation therapy to the chest. Modifiable cardiovascular risk factors, such as hypertension, can potentiate the risk of major cardiac events, and both behavioral and medical interventions can potentially reduce these risks. Clinical trials of these strategies could be performed to test their effectiveness and provide evidence to disseminate these findings as standards of care, helping to reduce morbidity and mortality, and, ultimately, improve overall quality of life for survivors of childhood cancer.
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